Bvf Inc Alpine Immune Sciences, Inc. Transaction History

Bvf Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.0 - $8.75 $1.94 Million - $2.43 Million	-277,601 Reduced 24.44%	858,339 $6.63 Million
Q3 2022 Nov 14, 2022	SELL	$6.89 - $9.39 $959,777 - $1.31 Million	-139,300 Reduced 10.92%	1,135,940 $8.18 Million
Q2 2022 Aug 15, 2022	SELL	$6.71 - $9.52 $2.11 Million - $2.99 Million	-314,255 Reduced 19.77%	1,275,240 $10.9 Million
Q3 2021 Nov 15, 2021	BUY	$8.19 - $11.31 $13 Million - $18 Million	1,589,495 New	1,589,495 $17 Million
Q2 2020 Aug 14, 2020	SELL	$2.77 - $12.1 $3.15 Million - $13.8 Million	-1,137,764 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.5 - $5.0 $48,835 - $69,765	-13,953 Reduced 1.21%	1,137,764 $4.46 Million
Q2 2019 Aug 14, 2019	SELL	$4.08 - $7.75 $204,000 - $387,500	-50,000 Reduced 4.16%	1,151,717 $4.85 Million
Q1 2019 May 15, 2019	BUY	$4.09 - $7.19 $2.28 Million - $4.02 Million	558,658 Added 86.88%	1,201,717 $8.24 Million
Q2 2018 Aug 14, 2018	SELL	$7.16 - $10.05 $234,132 - $328,635	-32,700 Reduced 4.84%	643,059 $4.87 Million
Q3 2017 Nov 14, 2017	BUY	$8.0 - $11.6 $5.41 Million - $7.84 Million	675,759	675,759 $7.84 Million

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.